Skip to content

    Fine Organic

    FINEORGNeutral
    Chemicals·13 May 2024
    Management Summary

    Fine Organic reported a sequential recovery in Q4 FY24, driven by stable raw material prices and favorable domestic demand, despite a high base effect from FY23. Management remains cautious about the European market and Red Sea logistics but is optimistic about long-term growth through capacity expansions in Thailand and a new 30-acre SEZ plot in Maharashtra. The company maintains a very strong, debt-free balance sheet with ₹900 crore in cash, earmarked for upcoming CAPEX and potential strategic acquisitions.

    Highlights

    8

    • Revenue for Q4 FY24 stood at ₹546 crore, showing a 12% QoQ recovery but an 8.3% YoY decline.

    • EBITDA margin for the quarter was 26.2%, significantly higher than the long-term sustainable guidance of 20-22%.

    • PAT for Q4 FY24 reached ₹114.6 crore, growing 21.6% QoQ, though down 23.3% YoY.

    • Full-year FY24 revenue declined 29.8% to ₹2,123 crore, as FY23 was considered an 'aberration' due to supply disruptions.

    • Cash and fixed deposits on the books increased to approximately ₹900 crore as of March 31, 2024.

    • Thailand project commissioning is expected by the end of June 2024 for trial production.

    • Exports contributed approximately 52% of total revenue in FY24, with Europe remaining the most affected market.

    • Patalganga facility is still in the ramp-up phase, expected to take another 2-4 years to reach full capacity utilization.

    Concerns

    1

    • Global Slowdown (Europe)

    What Changed2

    vs Q4 FY25

    Tone shiftGood → NeutralGuidance items5 → 4 (-1)
    Key financials

    Metrics

    6

    Periods

    2

    Headline

    5
    • Revenue
      ₹546 Cr
      YoY-8.3%QoQ+12%
    • EBITDA Margin
      26.2%
    • PAT
      ₹114.6 Cr
      YoY-23.3%QoQ+21.6%
    • ROCE
      24.7%
    • Cash and Fixed Deposits
      ₹900 Cr
      YoY+113.0%

    FY24

    1
    • Revenue
      ₹2,123 Cr
      YoY-29.8%

    Segment breakdown

    Geographic Mix
    52% Export Revenue Share
    List

    Guidance & targets

    4
    CategoryTargetPriority
    Capacity
    Thailand Project Commissioning
    End of June 2024
    		High
    Margin
    Sustainable EBITDA Margin
    20%-22%
    		High
    Volume
    Patalganga Facility Full Utilization
    4 years
    		Medium
    Capex
    SEZ Plant Construction Timeline
    20-23 months
    		Medium

    Risks & concerns

    5
    RiskSeverity

    Red Sea Crisis

    Lead times for exports to Europe and US have increased by 1 to 1.5 months. — Management acknowledged

    medium

    Global Slowdown (Europe)

    Europe is the worst affected region and demand is not expected to return quickly. — Management acknowledged

    high

    Regulatory Approval Delays

    Long approval times for new products from global customers and regulatory bodies (FDA, FSSA) delay commercialization. — Management acknowledged

    medium

    Areas of Evasion(2)

    • Specific volume growth numbers (stated policy not to disclose)
    • Specific details on acquisition targets

    Q&A highlights

    3

    “As of now, I don't see much difference than the last quarter, the raw material prices are quite stable and demands are also almost more or less similar like last quarter.”

    Confirms that the sequential improvement is not a one-off and that the current demand environment is stable.

    asked by Nitesh Dhoot, Dolat Capital

    2 min read5 chapters

    Detailed Narrative

    01

    Q4 Recovery Amidst High Base Normalization

    Fine Organic saw a 12% sequential revenue growth in Q4 FY24 to ₹546 crore, signaling a recovery from previous quarters. Management emphasized that FY23 was an 'aberration' due to extreme supply-side disruptions and price volatility, making YoY comparisons (down 8.3%) less meaningful. EBITDA margins remained robust at 26.2%, though management reiterated a long-term sustainable target of 20-22% as market conditions normalize.

    02

    Strategic Capacity Expansion: Thailand and SEZ

    The Thailand project is nearing a critical milestone with trial production expected to commence by the end of June 2024. This facility will produce a niche product currently made by only two other global players. Additionally, the company has been allotted 30 acres in a Maharashtra SEZ, which will primarily serve export markets. Construction is expected to take roughly two years once environmental clearances are obtained.

    03

    Patalganga Ramp-up and Product Monetization

    The Patalganga facility, which started in March 2022, is the only plant currently with significant spare capacity. Management expects it will take another 2 to 4 years to reach full utilization as they gradually monetize new food-grade products. Other plants are currently running at optimal capacity, limiting immediate volume growth until new facilities come online.

    04

    Robust Balance Sheet and M&A Outlook

    The company has aggressively repaid debt, reaching a near-zero borrowing level, while cash reserves have swelled to ₹900 crore. This 'war chest' is intended for the upcoming SEZ CAPEX, potential international plant setups, and strategic acquisitions. Management is actively evaluating opportunities that complement their existing oleochemistry expertise and product range, focusing on infrastructure and product fit rather than just financial metrics.

    05

    Navigating Global Headwinds and Logistics

    While domestic demand remains strong, the global slowdown🌐—particularly in Europe—continues to weigh on performance. The Red Sea crisis has further complicated exports, adding 1 to 1.5 months to lead times. Despite these challenges, management noted that raw material prices for vegetable oils have stabilized, providing a more predictable operating environment for the coming months.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.